Skip to main content

Table 3 EORTC quality of life scores by treatment arm

From: Effects on quality of life of weekly docetaxel-based chemotherapy in patients with locally advanced or metastatic breast cancer: results of a single-centre randomized phase 3 trial

  Mean baseline score (SD) Mean 6 weeks score (SD) Mean difference (SD)  
  3-weekly Weekly 3-weekly Weekly 3-weekly Weekly P value*
  N = 48 N = 41 N = 48 N = 41    
Global QoL 62.8 (22.8) 64.0 (21.2) 67.9 (16.0) 60.0 (19.0) 5.0 (26.0) -3.5 (20.5) 0.03
Functional scales        
Physical functioning 86.3 (16.6) 81.9 (19.6) 82.3 (16.8) 78.0 (18.0) -4.0 (11.8) -3.9 (14.3) 0.64
Role functioning 84.7 (22.2) 79.3 (26.0) 84.0 (21.2) 72.0 (23.4) -0.7 (22.3) -7.3 (24.7) 0.02
Emotional functioning 59.2 (23.5) 60.4 (22.2) 71.5 (19.1) 64.8 (24.4) 12.3 (21.6) 4.5 (18.5) 0.055
Cognitive functioning 88.9 (14.7) 89.8 (21.0) 90.3 (14.9) 83.7 (23.7) 1.4 (19.1) -6.1 (18.5) 0.055
Social functioning 81.6 (21.5) 80.5 (25.0) 80.2 (26.6) 69.5 (28.6) -1.4 (32.8) -11.0 (29.7) 0.07
Symptoms        
Pain 23.6 (27.9) 26.0 (25.3) 15.3 (19.1) 22.4 (19.9) -8.3 (23.8) -3.7 (19.9) 0.08
Loss of appetite 13.2 (23.6) 13.8 (23.5) 15.3 (21.7) 14.6 (21.1) 2.1 (29.5) 0.8 (24.1) 0.86
Constipation 13.9 (16.6) 15.4 (24.8) 17.7 (23.9) 20.0 (28.0) 4.3 (26.6) 5.8 (31.9) 0.71
Financial 18.8 (26.5) 19.5 (30.7) 15.3 (23.8) 35.0 (33.3) -3.5 (22.0) 15.4 (37.3) 0.0007
Fatigue 19.4 (19.7) 24.1 (25.0) 31.6 (19.0) 36.9 (20.6) 12.2 (16.0) 12.7 (26.1) 0.39
Nausea/vomiting 5.2 (12.0) 7.3 (14.5) 17.4 (25.0) 19.5 (22.6) 12.2 (24.0) 12.2 (21.4) 0.87
Sleeping disturbance 27.7 (28.9) 40.0 (31.3) 22.9 (26.8) 29.2 (32.2) -5.7 (28.1) -10.8 (28.6) 0.90
Diarrhoea 5.6 (14.3) 2.6 (9.0) 9.0 (17.9) 12.2 (20.8) 3.5 (19.7) 9.4 (20.2) 0.31
Dyspnoea 5.6 (12.6) 14.6 (25.9) 9.0 (16.5) 19.2 (21.2) 3.5 (15.7) 4.2 (25.2) 0.10
  1. SD: standard deviation; * bold p-values are statistically significant